TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: active days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: messages read
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: two-year mortality RDs
Endpoint domain: Mortality/survival
Primary endpoint: gastrointestinal bleeding RDs
Endpoint domain: Adverse events/effects
Primary endpoint: ODI score at 12 months after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS for back pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: FSAm-NPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erosive dentin wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %SMHl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tinnitus-related handicap
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative consumption of sufentanil in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe pain within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of binge-eating days per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bowel cleansing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pulse rate decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cooperation increase
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Balance (static and dynamic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit-to-stand ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Culture positivity of conjunctiva samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: improvement of postoperative pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blockade of the superior trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorder Society‐Unified Parkinson's Disease Rating Scale III (MDS‐UPDRS‐III) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCID in EQ-5D-3L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hip and knee extensors strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Body Function (BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of IES-R
Endpoint domain: Adverse events/effects
Primary endpoint: adequate serological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetite loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Q max at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Post-void residual (PVR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline FEV1 at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of K-wire insertions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Negative experiences in the category cold
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lower body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: greater self-reported energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Piriformis length improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SLR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: LEFS improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Hcy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Action Research Arm Test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin Scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mineralized tissue formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant bone level stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: moisturizing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: irritation assessment
Endpoint domain: Adverse events/effects
Primary endpoint: anti-septic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of clinical pulmonary infection score (CPIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (HRQoL) at 3 months post-surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Microbial abundance of Streptococcaceae, Leuconostacaceae, and Pasteurellaceae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metabolite levels (Gly Arg Val, phenylacetic acid, 1H-Indole-4-carbaldehyde)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: KTT (Keratinocyte proliferation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KTW (Keratinocyte migration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: filling reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in mental well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: diabetes remission without the need for medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in affective functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in TA symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: complications (e.g., perforation, pneumomediastinum)
Endpoint domain: Adverse events/effects
Primary endpoint: number of correct trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-abdominal insufflation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: xiphoid-umbilical distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in early post LSG upper GIT symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Less EGD evident reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of renal scarring following APN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cryptosporidium shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total stool weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of diarrheal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proactive protection motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: passive protection motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time from start to IOF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of feeding volume taken during the initial 5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with discordant AVA and mean gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reclassification of patients with severe AS to moderate AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemoptysis cessation at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hemoptysis amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for bronchial artery embolization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in mMRC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Borg scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: incidence of vomit
Endpoint domain: Adverse events/effects
Primary endpoint: Hearing gain at PTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total children's sleep duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: quality of bedtime routines
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: parental mood disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of increase in RS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kidney disease-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to the first clinical seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: risk of clinical seizures
Endpoint domain: Adverse events/effects
Primary endpoint: risk of drug-resistant epilepsy
Endpoint domain: Adverse events/effects
Primary endpoint: LDL aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activities balance confidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in the SDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in nicotine dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Fagerstrom test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First revascularizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total revascularizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percutaneous coronary intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Documented DNH orders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stricture formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived social support (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Quality of Life (QOL) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Emotional self-efficacy subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Active coping score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in IGF‐II serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IGF2R levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI correlation with IGF2R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: load to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percent increase in cross‐sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Utilization of sugammadex as primary reversal agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of neuromuscular blockade (NMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion of hormonal contraception effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of QFR-guided PCI strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost-effectiveness of QFR-guided PCI strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of opioid diversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS reduction at +48 hours
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experience of sexual harassment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of clinical bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: day 28 ACM rate
Endpoint domain: Mortality/survival
Primary endpoint: investigator-assessed clinical cure at TOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SGRQ improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CAT improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TDI improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AF recurrence after catheter ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction of the intake of medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concordance with reference quantitative testing of VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Same-day clinical review obtained
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Test failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary protein-to-creatinine ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with mesangial hypercellularity (M1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with segmental glomerulosclerosis (S1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial diversity and anaerobic richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biofilm composition changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in GRO-alpha and EGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable outcome (improvement of ventilatory parameters or extubation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: achievement of a ≥ 90% improvement in Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Physician's Global Assessment of clear/almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of postoperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Control of haematoma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Control of synechiae formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive disease rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative POMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: preference for tutorial format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Speaking rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSIT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intelligibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Passive Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen uptake (V̇O2 peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power output (watts max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceptions of trust, safety and quality of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WOMAC function score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial JSW change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: dual-task gait speeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive dual-task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of normal delivery less than 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Vitamin D status (25(OH)DTOTAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean myocardial wall FWHM measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bicarbonate signal-to-noise ratio (SNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average daily GRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preparation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of the cataract procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Phacoemulsification energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of postoperative retching/vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: household income
Endpoint domain: Life impact
Endpoint subdomain: Financial circumstances
Primary endpoint: chance of obtaining a university degree
Endpoint domain: Life impact
Endpoint subdomain: Educational outcomes
Primary endpoint: satisfaction with health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in breast engorgement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in milk volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal SCFA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma LBP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fecal zonulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of leaflet thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck disability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast-Q scores in satisfaction with breasts
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body Image Scale questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain interference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol sorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 role-emotional domain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cobb angles improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral muscle strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite primary effectiveness endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hypoattenuated leaflet thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of digital retinal images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes